| INTRODUCTION
A growing proportion of individuals with type 2 diabetes mellitus (DM2) worldwide is attributed in large part to the increase in body fat mass, especially in intra-abdominal (visceral) region. 1 Visceral adipose tissue is regarded to be metabolically active endocrine organ, secreting a variety of pro-inflammatory adipokines, thus further leading to many cardiometabolic disorders. 1, 2 Simple anthropometric parameter of abdominal adiposity such as waist circumference (WC) is established and widely used in many investigations. [3] [4] [5] As early recognition and treatment of individuals with abdominal adiposity is of utmost importance in reducing cardiometabolic risk, some novel visceral adiposity markers, such as visceral adiposity index (VAI) and the lipid accumulation product (LAP) have been validated so far. 6, 7 The VAI is gender-specific mathematical model that uses both as magnetic resonance imaging. 6 The LAP is a gender-specific index based on a combination of WC and TG in its equation. 7 Both of these indexes are proposed as simple, accurate, and low-cost tools for the evaluation of visceral adipose tissue dysfunction and its associated cardiometabolic risk in adult population, [6] [7] [8] [9] [10] even superior than simple anthropometric parameters (e.g., BMI, WC).
These indexes were proposed as markers of insulin resistance and metabolic-associated disturbances in women with polycystic ovary syndrome (PCOS), implicating that VAI and LAP may be used as screening tool for young women who are susceptible to the development of diabetes and CVD. 11, 12 Furthermore, higher VAI 13 and LAP 14 were associated with metabolic syndrome (MetS), with the presence of DM2, 15, 16 and with chronic kidney disease (CKD), 9 showing even better discriminative power in relation to cardiometabolic risk than anthropometric parameters alone. 7, 12, 17 Even though a large number of studies in adult population indicate VAI and LAP as reliable markers of cardiometabolic risk advantageous over BMI and WC, [6] [7] [8] [9] [10] 12, 13, 17 there are another ones that report the opposite.
18-22
Considering contradictory results obtained from many studies so far, we aimed to examine the potential benefit of applicability of novel visceral adiposity indexes, such as VAI and LAP, over simple anthropometric indices and traditional lipid parameters in individuals with DM2. For non-diabetics group, inclusion criteria were fasting glucose <7.0 mmol/L and glycosylated hemoglobin (HbA1c) ≤6%. In addition, all participants with fasting glucose ≥5.6 mmol/L, but <7.0 mmol/L, underwent a 2-h oral glucose tolerance test (OGTT). Participants with 2-h postload glucose ≥11.1 mmol/L were excluded from the control group.
| MATERIALS AND METHODS

| Study population
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Exclusion criteria for all participants were as follows: type 1 diabetes mellitus, ethanol consumption >20 g/day, high-sensitivity C-reactive protein levels (hsCRP) >10 mg/L, liver disease, hypothyroidism or hyperthyroidism, patients on chronic dialysis, renal disease other than diabetic nephropathy, with a recent (6 months) history of acute myocardial infarction or stroke, pregnancy, usage of antiinflammatory medications in the last 6 months, usage of insulin or hypoglycemic agents for controls, as well as participants who were unwilling to enter the study.
All participants who used lipid-modifying drugs (55.5%) in our study used statins (100% of them), whereas the smaller number of them used fibrates, also (3.3%).
All the participants provided written informed consent. The study protocol was approved by the Ethical Committee of Primary Health
Care Center in Podgorica, Montenegro and the research was carried out in compliance with the Declaration of Helsinki.
| Anthropometric measurements
Basic anthropometric measurements: body height (cm), body weight (kg), and WC (cm) were obtained, and BMI was calculated, as described previously. Visceral adiposity index (VAI) was calculated using the formula: . where WC is expressed in cm, and TG in mmol/L.
| Biochemical analyses
The blood samples were taken between 7 and 9 hours a.m., after 12-14 hours of an overnight fast. Samples were left to clot for 30 minutes and then centrifuged at 3000 rpm for 10 minutes.
Serum samples were divided into aliquots and stored at −80°C, without prior thawing and re-freezing before analyses, except for glucose, which was determined immediately after the blood was drawn.
Another aliquot was collecting as a whole blood in K 2 EDTA for determination of HbA1c, and it was measured with immunoturbidimetric assay (Roche Cobas 400, Mannheim, Germany).
Serum levels of glucose, total cholesterol (TC), HDL-c, low-density lipoprotein cholesterol (LDL-c), TG, uric acid, bilirubin, aspartat aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamil transferase (GGT) were measured using standardized enzymatic procedures, spectrophotometrically (Roche Cobas 400). HsCRP) levels were determined using a nephelometric assay (Behring Nephelometer
Analyzer, Marburg, Germany).
Glomerular filtration rate was estimated by using creati- Blood pressure was measured as described previously. Multivariate logistic regression analysis was used to identify factors associated with risk for DM2 development. Multivariate analysis adjustment was made for all parameters which showed significant differences between two tested populations, exhibit significant correlations with other independent parameters, and associated with DM2 occurrence and development. Data were presented as odds ratio (OR) and 95% CI for odds. 
| RESULTS
In Table 1 are summarized demographic characteristics of studied groups. Diabetic patients were older (P<.001), had significantly higher BMI (P=.003) and WC (P<.001). Chi-square analysis showed unequal distribution of gender, subjects who used hypolipemic and antihypertensive therapy (P<.001 for all).
T A B L E 1 Demographic characteristics of two study groups Statistical analysis showed that diabetic patients had significantly higher TG, LAP index, VAI, GGT, uric acid (P<.001 for all), ALT (P=.022), creatinine (P=.001), eGFR MDRD (P=.007), and hsCRP (P=.004) than controls. Also, diabetic patients had significantly lower HDL-c and total bilirubin level than control group (P<.001, and P=.028, respectively) ( Table 2) .
Results of Spearman's correlation analysis were presented in Table 3 . BMI and WC were highly positively correlated with ages, SBP, Logistic regression analysis was used to establish the associations of VAI, LAP index, and each parameter used in their equations with DM2 development (Table 4) . Predictors were unadjusted and adjusted for other parameters significantly different between study groups (Table 2) . Also, ages and hypolipemic therapy, which showed significant odds in univariate logistic regression analysis, were tested further in models to determine their independent predictions on DM2 development. WC kept independent predictions for DM2 development (Model 1 OR=1.050 P=.027; Model 3 OR=1.052, P<.001).
As WC rose for 1 cm, risk for DM2 development got higher for 5% In all models, ages and hypolipemic therapy were shown to be the independent predictors of DM2 development. Usage of hypolipemic therapy presented around two times higher risk of DM2 development (all Models, ROC analysis was used to discriminate subjects with DM2 from those who did not have it (Tables 5 and 6 The same models were used in ROC analysis as in logistic regres- (Table 6 ).
| DISCUSSION
The main finding of our study reveals that neither VAI nor LAP are superior to simple anthropometric indices (e.g., WC) and lipid parameters (e.g., HDL-c) for DM2 prediction.
Logistic regression analysis showed that VAI lost its independent predictive role, but LAP kept its independent prediction of DM2 development, after adjustment for confounding factors ( Table 4) .
As more than 60%-70% of DM2 patients are affected by nonalcoholic fatty liver disease (NAFLD), and as that diabetic individuals with NAFLD have increased risk for long-term diabetes complications such as chronic kidney disease and CVD, 25 we determined liver enzymes activity in all participants. Moreover, we determined uric acid and total bilirubin levels, regarding that hyperuricemia and low total bilirubin levels are associated with increased risk of DM2 and its complications. 26 In addition, we determined creatinine levels and calculated eGFR in all subjects, as studies report the association of high creatinine levels, and low eGFR levels with an increased risk of DM2, as well as its complications.
27,28
A ROC analysis was used to discriminate subjects with DM2 from those who did not have it and showed that good accuracy of the applied procedures was only achieved with models which were consisted of parameters used in VAI (BMI, WC, HDL-c, TG) and LAP (WC, TG) indexes equations, respectively (AUC=0.819 and AUC=0.800, respectively), but not with VAI and LAP indexes themselves (Table 6 , Figure 1 ).
The majority of previous studies reported VAI and LAP to be reliable indices in prediction of many metabolic disturbances. [6] [7] [8] [9] [10] 12, 13, 17 Amato et al. 8 reported superiority of the VAI, to other anthropo- in discriminating subjects with DM2 from those who did not have it (Table 6) .
Also, previous studies reported that LAP better than other variables (e.g., BMI and WC) predicted MetS, 14 DM2, 12,17 and CVD. Similarly, some other investigations reported simple anthropometric measures, BMI and WC to be more accurate than VAI in prediction of the presence of MetS, 20 hepatic steatosis, 21 and incident CVD. 22 In addition, it has been reported that although LAP was an independent predictor of cardiovascular events even in normal weight subjects, it had no advantageous capabilities over other anthropometrics indices. 18 Similarly, Dai et al. 9 showed that neither VAI nor LAP index was superior for identifying individuals with CKD over BMI in the male gender.
In our study, logistic regression analysis reported WC to be the independent predictor of DM2 development both in unadjusted and adjusted model. As WC rose for 1 cm, the risk for DM2 development got higher for 5% (Model 1) and 5.2% (Model 3), respectively (Table 4) . Our results are in line with previous findings 1, 29 suggesting that visceral adiposity is the independent risk factor for DM2. Visceral adipose tissue is significant source of variety of pro-inflammatory adipo-and cytokines which reach the liver, thus impairing insulin signaling, with consequent insulin resistance occurrence, lipid accumulation, and metabolic disorders.
1,2
Although Computed Tomography (CT) represents the "gold standard method" for evaluating the quantification of visceral adipose tissue, it is not suitable diagnostic procedure in routine clinical practice due to its high cost and radiation exposure. Therefore, WC is regarded to be simple, easily obtained anthropometric parameter that can estimate visceral obesity in primary care settings. 30 Furthermore, HDL-c was also shown to be the independent predictor of DM2. Rise in HDL-c by 1 mmol/L reduced the probability of DM2 development by 85.8% (Model 1) ( Table 4 ).
Other studies also showed low HDL-c to be the independent risk factor for DM2.
31,32
Gupta et al. 31 found that increase in HDL-c by 1 mmol/L decreased the probability of DM2 by 28%. Another important finding of our study was that in all models, ages and hypolipemic therapy were shown to be the independent predictors of DM2 development. Relationship between ages and DM2 was also reported previously. 29 In our study, as person got older by 1 year, the probability for DM2 development rose for 5.0% in unadjusted and for 6.4% in adjusted model.
In this study usage of hypolipemic therapy presented around 3.12 time higher risk of DM2 development in unadjusted model, and 2 times higher risk of DM2 occurrence in adjusted model. It is important to note that all participants in our study who used hypolipemics, used statins. Our results are in line with recent studies which also showed an increased risk of DM2 with statins usage. 34, 35 Cederberg et al. 34 in a large study comprised of about 9,000 non-diabetic participants, during a 6-year follow-up showed that statin treatment increased the risk of DM2 by 46%, mainly due to decrease in insulin sensitivity (by 24%) and insulin secretion (by 12%), compared with individuals without statin treatment.
Although this study has cross-sectional design which precludes causal inferences, we speculate that novel visceral adiposity indexes, such as VAI and LAP, have no advantages over simple anthropometric indices or lipid parameters in prediction of DM2 risk. Large longitudinal studies are needed to further examine the potential benefits of VAI and LAP in DM2 prediction.
| CONCLUSION
Visceral adiposity index and Lipid accumulation product may not be better than parameters that enter its equation in type 2 diabetes prediction.
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